Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133<sup>+</sup> cells in ischemic refractory cardiomyopathy trial (RECARDIO)
Stem Cell Research &Therapy
Cell therapy with bone marrow (BM)-derived progenitors has emerged as a promising therapeutic for refractory angina (RA) patients. In the present study, we evaluated the safety and preliminary efficacy of transcatheter delivery of autologous BM-derived advanced therapy medicinal product CD133+ cells (ATMP-CD133) in RA patients, correlating perfusion outcome with cell function.
Reference
Bassetti B, Carbucicchio C, Catto V, Gambini E, Rurali E, Bestetti A, Gaipa G, Belotti D, Celeste F, Parma M, Righetti S, Biava L, Arosio M, Bonomi A, Agostoni P, Scacciatella P, Achilli F, Pompilio G. Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133<sup>+</sup> cells in ischemic refractory cardiomyopathy trial (RECARDIO). Stem Cell Res Ther 2018 Sep 14;9(1):235. doi: 10.1186/s13287-018-0969-z.